Who
Fred A. Middleton
Director and 10% owner
Company insider
Files Form 4 as: Director and 10% owner, CalciMedica; Director, Chimerix; Director, Endocyte; Director and 10% owner, Stereotaxis; Director and 10% owner, Pacira BioSciences; Director and 10% owner, Cardionet; Director and 10% owner, Favrille.
In numbers
- Trades disclosed
- 655
- Buys
- 51
- Sells
- 28
- Bought
- $18.7M
- Sold
- $34.8M
- Companies
- 7
- Companies where not an officer
- 7
- First trade
- 7 Mar 2006
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $200K248,972 at $0.8033 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $199K248,972 at $0.80 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,562 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,687 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —42,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —21,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —21,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —35,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —35,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerixoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerix | SEC FORM 4 Code D | $342K40,000 at $8.55 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerix | SEC FORM 4 Code D | $513K60,000 at $8.55 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerix | SEC FORM 4 Code D | $23.7M2,776,093 at $8.55 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerix | SEC FORM 4 Code D | $4.5M531,861 at $8.55 | filing |
| 21 Apr 2025filed 21 Apr 2025 | Chimerix | SEC FORM 4 Code D | $1.8M207,523 at $8.55 | filing |
| 6 Dec 2024filed 6 Dec 2024 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $13K4,800 at $2.65 | filing |
The newest 500 lines are listed; the numbers count every line.
News
No headline names them, or the companies they trade most, lately.